a_dose_of_drug_smallbanner_R2

Blog News - A Dose of Drug Development is a web publication produced by Integrium. The blog post content included conveys subjects of discussion and practice in the drug development process along with real-time Integrium activity. Readers interested in following are welcome to comment and interact on the Integrium website blog space.


Join Integrium, LLC in San Francisco at the Microbiome Breakfast Round-Table: J.P. Morgan

During J.P. Morgan 36th Annual Healthcare Conference
Hosted by Integrium, LLC and EisnerAmper

The Microbiome breakfast will allow networking between Microbiome Companies
and Venture Capitalists who are active in the Microbiome space:

The following presentations and topics will be discussed:

  • Clinical lessons learned with respect to gut, dermatology, and metabolic microbiome studies.
  • Unique exit strategies with respect to Microbiome companies and how they differ from therapeutic companies.
  • A Venture Capitalist perspective on how they view Microbiome therapeutics from 510(k).
  • View or perspective from Microbiome sponsors on the unique challenges they see in the industry.

Microbiome-1

Meet the Experts and Learn Industry Secrets

Join Integrium, LLC and EisnerAmper Executives at our breakfast round-table during the week of the 2018 J.P. Morgan 36th Annual Healthcare Conference.

Integrium will be sharing their expertise within microbiome clinical trials, fecal sample collection lessons learned, tips to shorten the path to commercialization, exit strategies for microbiome companies, and alternative financing solutions. Integrium has worked on a solid number of Microbiome-related trials and has an extensive database of 2,500+ pre-screened patients whom are interested in microbiome skin and stool-based studies.

EisnerAmper, who has partnered with Integrium in the past on a number of events, will be covering a broad range of topics such as impact of tax reform on life sciences companies, the current life sciences financing environment, and beyond.

A Time To Collaborate and Connect

Come ready to discuss, enjoy a light breakfast with coffee, and develop relationships with like-minded industry folks in the microbiome, biotech, medical device, diagnostic, and financial sectors.

Who: Microbiome Companies, Microbiome Venture Capital and Private Equity
When: January 10th, 2018
Where: EisnerAmper: 1 Market St # 620, San Francisco, CA 94105
Time: 8:00 - 10:00 AM PST

Microbiome

Please RSVP by December 22, 20 17

Please RSVP to:
Emily MacHale
Associate Director, Marketing & Research
Emily.MacHale@Integrium.com
Main Phone: (908)-375-2009
Mobile Phone: (201)-704-2066

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 505(b)(2) and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule II drugs and Oncology.

Check out our new website!
www.integrium.com


Integrium, LLC Executives to Attend American Association of Pharmaceutical Scientists

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be attending the American Association of Pharmaceutical Scientists (AAPS) in San Diego on November 12-15, 2017. Taking place at the San Diego Convention Center, Integrium is looking forward to connecting with industry folks and learning more about patient-centric innovations and opportunities.

The chance to be able to hear from top speakers, keynote presentations, and more is valuable to Integrium and their current initiatives in the biotechnology ecosystem. This conference provides the opportunity to connect with CEOs, scientists and clinical partners that are advancing Generic, 505b2 and other healthcare initiatives while finding solutions to improve patient-centric goals. Integrium welcomes CEOs, scientists and clinical partners to join them in finding potential ways to collaborate and develop partnerships for current and future opportunities.

Integrium will be available for meetings throughout the event and encourages guests reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 505(b)(2) and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule II drugs and Oncology.

Check out our new website!
www.integrium.com

To learn more about Integrium, contact:
Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Integrium, LLC to Discuss Alternative Financing Solutions for Biotech during J.P. Morgan 36th Annual Healthcare Conference Week

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be in San Francisco during the J.P. Morgan 36th Annual Healthcare Conference on January 8-11, 2018. Being in San Francisco during the conference over the past 7 years, Integrium is able to continue connecting with biotech, medical device, and diagnostic companies, while building new relationships and cross-pollinating a wide span of industry sectors.

The JPM Conference is expecting to host over 400 public and private companies, in addition to more than 8,000 guests. Being the largest healthcare investment conference in the industry, Integrium values the opportunity to connect with investors and like-minded folks looking to collaborate and develop strategic partnerships.

Integrium will be available for meetings January 8-11, 2018 and encourages guests to reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 505(b)(2) and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule II drugs and Oncology.

Check out our new website!
www.integrium.com

To learn more about Integrium, contact:
Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Integrium, LLC Executives to Attend 5th Microbiome R&D and Business Collaboration Forum: USA

By: Emily MacHale

Tustin, CA – Integrium Executives are attending the 5th Microbiome R&D and Business Collaboration Forum in San Diego on November 2-3, 2017; with the collaboration of the 2nd Probiotics Congress: USA. Integrium Executives are excited to network and share ideas with the projected over 400 attendees and 70 speakers that will be involved in roundtables, panel discussions, networking events, and more. More specifically, Integrium is looking forward to learning more about the innovative opportunities involving the human microbiome: the gut, skin, oral, genetic disease states and beyond.

Integrium is heavily invested in the microbiome space, currently conducting various dermatology and gut microbiome studies. In addition, Integrium’s clinical Phase I - IV unit (Orange County Research Center) has thousands of pre-screened healthy volunteers that participate (or want to participate) in upcoming fecal sampling studies. Having better knowledge of the microbiome is important to understanding numerous existing genetic diseases. Many genetic diseases require their own unique approach, and grasping the ins and outs of the microbiome can impact the way we tackle these innovative drug development goals.

Actively participating in the 5th Microbiome R&D and Business Collaboration Forum allows Integrium to broaden goals and initiatives for microbiome-based disease cures, provides opportunity to dip into recent findings, and to stay in touch with industry trends. With that, investors are able to join and find potential partnerships with early-stage biotechs and start-ups.

Integrium is available for meetings all day on November 2, 2017 and encourages guests reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a fullservice Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 5o5b2 and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include: Cardiovascular, Metabolic, Microbiome, Regenerative Medicine, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

For more information on Integrium’s microbiome clinical studies and initiatives, please visit us online at: http://www.integrium.com/our-expertise/microbiome/

Check out our new website!
www.integrium.com

To learn more about Integrium, contact:
Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Integrium, LLC Executives to Attend Cell & Gene Meeting on the Mesa

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be attending the Cell & Gene Meeting on the Mesa on October 4-6, 2017 in La Jolla, CA. The annual event brings together top executives in the life sciences industry and guests that are eager to join forces to find solutions for the healthcare field. With a focus in regenerative medicine, the Cell & Gene Meeting on the Mesa highlights the importance of gene therapy and the crucial role it plays in advancing a wide range of therapeutic areas and medicine.

The event provides meeting opportunities by promoting their Partnering Forum and use of an online system to connect guests with industry leaders. The system allows Integrium to collaborate and learn more about the regenerative medicine field, new trends, and potential partnerships that could be available.

Integrium will be available for meetings throughout the event and encourages guests to connect with Mike Loftus, Executive Director of Business Development via the online partnering system: Partnering System. If you have trouble viewing the link, please contact Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com.

To learn more about Integrium’s regenerative medicine experience, please visit us online at: Integrium Expertise.

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Regenerative Medicine, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!

www.integrium.com

To learn more about Integrium, please contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009


Integrium, LLC to Attend RESI Boston 2017

By: Emily MacHale

Tustin, CA - Integrium, LLC announced they will be attending RESI Boston 2017 on September 26th, 2017. RESI allows life science companies to connect with investors that come from different backgrounds related to Virtual Pharma, Angels, Venture Philanthropy, Patient Groups, Corporate Development, and more. With over 800 guests coming from 38 U.S. states and 25 countries, attendees are able to meet and discuss potential opportunities for success for their organizations. Encouraging in person meetings with pharma companies or service providers and investors, RESI is a place for creating new connections, continuing business relationships, and mainly finding capital.

With there being over 1,200 meeting slots and participating as active members in the life sciences community, Integrium is able to share the various funding options that are available within their organization, clinical trial expertise in a number of therapeutic areas, and their platform for CRO and investor success. Integrium prides themselves on helping biotechs of all sizes attain clinical data so they can raise their next round of capital. Therefore, it is important to always be thinking of a key clinical partner that can guide you through the challenges of the drug development process.

Integrium is available for meetings throughout the day on September 26th and welcomes all life sciences companies, investors, and service providers. To schedule a meeting, please contact Emily MacHale at Emily.MacHale@integrium.com or connect with Mike Loftus, Executive Director of Business Development via the RESI partnering system: http://resiboston17.meeting-mojo.com

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the New Chemical Entity, 505(b)(2), and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!

www.integrium.com

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHale@Integrium.com
908-375-2009